Chroma Therapeutics

company

About

Chroma Therapeutics is focused on the R&D of novel small molecule drugs based on chromatin biology and cell accumulation.

  • 51 - 100

Details

Last Funding Type
Debt Financing
Last Funding Money Raised
$15M
Industries
Biotechnology,Developer Platform,Information Services
Founded date
Jan 1, 2000
Number Of Employee
51 - 100
Operating Status
Active

Chroma Therapeutics is a privately-held biotechnology company focused on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. Chroma is the first company to systematically assemble intellectual property in chromatin biology and has established a strong network of academic collaborators. Chroma aims to build substantial shareholder value through the creation of a broad and innovative product pipeline aimed at the treatment of high-prevalence cancers and inflammatory disorders.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$68M
Chroma Therapeutics has raised a total of $68M in funding over 2 rounds. Their latest funding was raised on May 5, 2010 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 5, 2010 Debt Financing $15M 1 Hercules Capital Detail
Apr 3, 2006 Series C $53M 1 Phase4 Ventures Detail

Investors

Number of Lead Investors
Number of Investors
2
2
Chroma Therapeutics is funded by 2 investors. Hercules Capital and Phase4 Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Debt Financing
Phase4 Ventures Yes Series C